Evidence map›Paper›PMID 31430056›Full record

Trial reportImmunity, inflammation and disease2019

Analysis of cellular and soluble profiles in QuantiFERON nonconverters, converters, and reverters in the Gambia.

Lydia Medawar, Hatimi Mohd Tukiman, Georgetta Mbayo, Simon Donkor, Olumuyiwa Owolabi, Jayne S Sutherland

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Immunity, inflammation and disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Overlooked, dismissed, and downplayed: reversion ofEuropean respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Frontiers in immunology · 2021
    Article
  13. Phenotype Definition for "Resisters" toFrontiers in immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lydia MedawarVaccines and Immunity Theme, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Fajara, Gambia.
Hatimi Mohd TukimanDepartment of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Georgetta MbayoVaccines and Immunity Theme, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Fajara, Gambia.
Simon DonkorVaccines and Immunity Theme, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Fajara, Gambia.
Olumuyiwa OwolabiVaccines and Immunity Theme, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Fajara, Gambia.
Jayne S SutherlandVaccines and Immunity Theme, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Fajara, Gambia.ORCID 0000-0002-7083-4997

Funding

Medical Research Council MC_U190071468Medical Research Council MC_UP_A900_1122
6 · The paper itself

Abstract

backgroundTuberculosis (TB) is the leading cause of death from a single infectious agent worldwide. The immune system is capable of clearing the pathogen before establishment of latent infection but the mechanisms for this are not yet understood.

methodsThis study analysed highly exposed household contacts (HHC) of TB index cases who were categorised according to QuantiFERON (QFT) results at recruitment and 6 months. Seventeen (17) QFT nonconverters, 14 QFT converters, 18 QFT reverters and 18 latent TB infection (LTBI) were analysed. Supernatants generated following QFT stimulation at both time-points were analysed using a 64-plex cytokine array. Flow cytometry was performed on QFT converters and nonconverters at baseline only.

resultsInterleukin-2 (IL-2), IL-5, IL-13, APRIL, IL-17A, IP-10, MIP-1ß, sIL-6rb, OPN, and sTNFR2 were all significantly higher in the QFT converters compared with nonconverters at baseline. Levels of interferon-α2 (IFN-α2) and IL-2 were significantly lower in QFT reverters compared with nonconverters at baseline. Analysis of Ag-specific IL-2 levels resulted in an area under the curve (AUC) of 0.93 (95% confidence interval [CI], 0.84-1.00) for QFT converters compared to nonconverters and an AUC of 0.80 (0.65-0.95) for QFT reverters compared with LTBI. Purified protein derivative (PPD)-specific CD4 + CD26 + IFN-γ + cells were significantly increased (P = .0007) in QFT nonconverters compared with QFT converters at baseline.

conclusionsOur results provide insight into the underlying mechanisms of resistance to sustained Mycobacterium tuberculosis infection.

Indexed as

CytokinesImmunity, CellularLatent TuberculosisMycobacterium tuberculosisAdolescentAdultFemaleGambiaHumansLongitudinal StudiesMaleMiddle AgedCytokinescytokinesinflammationQFT conversionQFT reversionTh17 cellstuberculosis

Identifiers

PMID31430056
PMCPMC6842814

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.